Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H1 2017 Summary 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders. 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Genetic Disorders which include indications Psychiatric Disorders, Bipolar Disorder (Manic Depression), Schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Major Depressive Disorder, Anxiety Disorders, Cognitive Disorders, Fragile X Syndrome, Inflammatory Pain, Irritable Bowel Syndrome, Migraine, Neuropathic Pain, Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Social Anxiety Disorders (SAD) and Tourette Syndrome. The latest report 5-Hydroxytryptamine Receptor 7 - Pipeline Review, H1 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects - The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development Adamed Sp z oo Astellas Pharma Inc Braeburn Pharmaceuticals Inc H. Lundbeck A/S Johnson & Johnson Reviva Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles ADN-1184 - Drug Profile Product Description Mechanism Of Action R&D Progress ADN-3662 - Drug Profile Product Description Mechanism Of Action R&D Progress ATI-9242 - Drug Profile Product Description Mechanism Of Action R&D Progress DDD-028 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-18038683 - Drug Profile Product Description Mechanism Of Action R&D Progress lurasidone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress RP-5063 - Drug Profile Product Description Mechanism Of Action R&D Progress SERx-519 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize Alpha 2 Adrenergic Receptor and Antagonize 5-HT7 and 5-HT5A Receptors for Psychiatric Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile Product Description Mechanism Of Action R&D Progress vortioxetine hydrobromide - Drug Profile Product Description Mechanism Of Action R&D Progress 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones Featured News & Press Releases Jun 09, 2017: Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression May 22, 2017: Sunovion Announces Positive Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression at Annual American Psychiatric Association Meeting May 16, 2017: Sunovion to Present Data on Latuda (lurasidone HCl) at Annual American Psychiatric Association Meeting Mar 31, 2017: Sunovion to Present Data on LATUDA (lurasidone HCI) at the 25th European Congress of Psychiatry Feb 27, 2017: Sunovion Announces Positive Topline Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression Jan 28, 2017: Sunovion's Latuda (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia Dec 02, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 55th Annual Meeting of the American College of Neuropsychopharmacology Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH) Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress Aug 08, 2016: Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda (lurasidone HCl) in the Treatment of Schizophrenia Jun 02, 2016: Trintellix (vortioxetine) Now Available in U.S. Pharmacies May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016 May 16, 2016: Takeda and Lundbeck Present Vortioxetine Data at the American Psychiatric Association 2016 Annual Meeting Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Adamed Sp z oo, H1 2017 Pipeline by Astellas Pharma Inc, H1 2017 Pipeline by Braeburn Pharmaceuticals Inc, H1 2017 Pipeline by H. Lundbeck A/S, H1 2017 Pipeline by Johnson & Johnson, H1 2017 Pipeline by Reviva Pharmaceuticals Inc, H1 2017 Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
